TGA bans compounding pharmacies from replicating weight loss drugs

Australia's TGA will ban compounding pharmacies from making off-brand versions of weight loss drugs Ozempic and Mounjaro due to safety concerns. The move follows a loophole enabling pharmacies to replicate the drugs, leading to supply shortages. The TGA cited risks including unreported side effects and challenges in ensuring product quality. Patients with compounded medications are advised to consult their doctors. Investigations are ongoing, and legislative changes are being advocated for better public protection.